We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Obviously, Dupixent in COPD has a broader label ... They overlap ever so slightly, I think, in the above 300 EOS level in the Type 2 COPD patient population. But I think the compliment of the ...

SNY earnings call for the period ending December 31, 2024.

Dupixent is an eczema treatment whose rights ... and management of various kinds of cancers. Its 300-plus Vysis DNA FISH probes are specially designed for breast, hematology, bladder, lung ...

COPD affects more than 300 million people globally and is the ... For Nucala, is the exacerbation data competitive with Dupixent and have you shown an FEV benefit, I mean, if not, your statements ...

In the BOREAS and NOTUS trials, Dupixent cut the rate of exacerbations by 30% and 34%, respectively, and both those studies specifically enrolled patients with BEC levels of 300 cells/μL or above.

The lung disease affects more than 300 million people globally ... Sanofi and Regeneron's big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

And that's a mix of roughly $300 million rheum ... So in several large markets, we actually are ahead of Dupixent. And some of that has to do with the way that the label worked during our initial ...

Chronic obstructive pulmonary disease (COPD) is a significant global health concern, ranking as the third-leading cause of mortality worldwide and affecting around 480 million people. 1,2 Its hallmark ...

Where Honda’s CRF300 Rally is the class-leader for rally-style trailies, it finally has some competition from Chinese brand Voge and their Rally 300. For those of you who haven’t heard of Voge ...